The study was supported by the Helsinki University Central Hospital, the Finnish Medical Foundation, the Finnish Brain Foundation and the Emil Aaltonen Foundation supports.
.. In October 2008′ Oncophage Cancer Vaccine Receives European Orphan Drug Designation for BrainAntigenics Inc. announced that Oncophag was a positive recommendation for orphan drug status for the treatment of glioma by the Committee for Orphan Medical Products granted of the European Medicines Agency . This designation provides Antigenics with, among other benefits, 10 years of potential market exclusivity if the product to be marketed in the European Union approved. This is the second indication for which the EMEA has granted orphan drug Oncophage -. In April 2005, Oncophage received orphan drug designation in the European Union for the treatment of renal cell carcinoma .– beta – lactams can is still the best first row of initial therapy for skin and skin structure infections be caused by of MRSA.